TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients

TerminadoClinicalTrials.gov

ID: NCT01866904Tipo: OBSERVATIONALInicio: 19 de jun de 2013Fin estimado: 31 de mar de 2017

Traducción no disponible, mostrando original

Resumen

THis study is intended to provide contemporary data on the burden of disease in patients 1 to 3 years post-MI, including a description of patient characteristics, current treatment patterns, rate of major CV events, and healthcare resource utilization in a 'real world' patient population at high atherothrombotic risk.

Descripción detallada

TIGRIS is a multinational, multi-centre, observational, prospective, longitudinal cohort study which will include stable CAD patients with history of MI 1-3 years ago and high risk of developing atherothrombotic events in a real world setting. The follow-up period is 3 years. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. Patients will not receive experimental intervention or experimental treatment as a consequence of their participation in the study.

Elegibilidad

Edad mínima: 50 YearsSexo: ALL

Criterios de inclusión

\- Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 of the following risk factors: age ≥ 65 years; diabetes mellitus requiring medication; documented history of a second prior presumed spontaneous MI (\>1 year ago); documented history of angiographic evidence of multivessel coronary artery disease; chronic renal dysfunction.

Criterios de exclusión

Presence of serious co-morbidities in the opinion of the investigator which may limit life expectancy (\<1 year)
Current participation in a blinded randomized clinical trial.
Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient
Patients receiving treatment of ticagrelor beyond 12 months, or off label use of ticagrelor.

Ubicaciones

Research Site

Buenos Aires, Argentina

Research Site

Corrientes, Argentina

Research Site

Córdoba, Argentina

Research Site

Mendoza, Argentina

Research Site

Salta, Argentina

Research Site

Santa Fe, Argentina

Patrocinadores

PrincipalAstraZeneca

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcar... | EligiMed